Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 6504518, 6 pages
https://doi.org/10.1155/2017/6504518
Review Article

The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases

1College of Bioscience and Biotechnology and College of Animal Science and Technology, Hunan Agricultural University, Changsha 410128, China
2Hunan Province University Key Laboratory for Agricultural Biochemistry and Biotransformation, Hunan Agricultural University, Changsha 410128, China
3Hunan Co-Innovation Center for Utilization of Botanical Functional Ingredients, Changsha 410128, China

Correspondence should be addressed to Xiaosong Wu; moc.621@1370gnosoaixuw and Jun Fang; nc.ude.uanuh@3791nujgnaf

Received 2 February 2017; Accepted 8 March 2017; Published 13 March 2017

Academic Editor: Mikhail A. Gavrilin

Copyright © 2017 Shuang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Danaei, G. M. Singh, C. J. Paciorek et al., “The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and western diet in 1980 and 2008,” Circulation, vol. 127, no. 14, pp. 1493–1502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. A. N. Orekhov, “Mechanisms of atherogenesis and development of anti-atherosclerotic therapy,” Current Pharmaceutical Design, vol. 21, no. 9, pp. 1103–1106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Naghavi, H. D. Wang, R. Lozano et al., “Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013,” The Lancet, vol. 385, no. 9963, pp. 117–171, 2015. View at Publisher · View at Google Scholar
  4. M. Bastien, P. Poirier, I. Lemieux, and J.-P. Després, “Overview of epidemiology and contribution of obesity to cardiovascular disease,” Progress in Cardiovascular Diseases, vol. 56, no. 4, pp. 369–381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Q. Purnell, B. Zinman, J. D. Brunzell et al., “The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study,” Circulation, vol. 127, no. 2, pp. 180–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. N. Orekhov, I. A. Sobenin, M. A. Gavrilin et al., “Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy,” Current Pharmaceutical Design, vol. 21, no. 9, pp. 1172–1179, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Teo, S. Lear, S. Islam et al., “Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study,” JAMA, vol. 309, no. 15, pp. 1613–1621, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. M. S. Khan, G. Murtaza, M. Usman et al., “Evidence based study of side effects of drugs used in the treatment of diabetes mellitus,” African Journal of Microbiology Research, vol. 6, no. 24, pp. 1805–1808, 2012. View at Publisher · View at Google Scholar
  9. M. Yoshikawa, H. Fujita, N. Matoba et al., “Bioactive peptides derived from food proteins preventing lifestyle-related diseases,” BioFactors, vol. 12, no. 1–4, pp. 143–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. A. N. Orekhov, “Evidence based efficacy of herbal preparations in ageing associated cardiovascular disorders,” Phytomedicine, vol. 23, no. 11, pp. 1065–1067, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Giansanti, L. Leboffe, G. Pitari, R. Ippoliti, and G. Antonini, “Physiological roles of ovotransferrin,” Biochimica et Biophysica Acta—General Subjects, vol. 1820, no. 3, pp. 218–225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Zachary, “Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor,” American Journal of Physiology—Cell Physiology, vol. 280, no. 6, pp. C1375–C1386, 2001. View at Google Scholar · View at Scopus
  13. Y. Huang, “Oxidative stress and endothelial dysfunction in hypertension and diabetes,” Clinical and Experimental Pharmacology and Physiology, vol. 40, p. 8, 2013. View at Google Scholar
  14. M. O. G. Albarran, S. Calvo, M. Carrasco et al., “Insulin resistance and endothelial dysfunction in patients with hypertension and metabolic syndrome,” Journal of Hypertension, vol. 27, pp. S220–S220, 2009. View at Google Scholar
  15. T. Münzel, C. Sinning, F. Post, A. Warnholtz, and E. Schulz, “Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction,” Annals of Medicine, vol. 40, no. 3, pp. 180–196, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Virdis, E. Duranti, and S. Taddei, “Oxidative stress and vascular damage in hypertension: role of angiotensin II,” International Journal of Hypertension, vol. 2011, Article ID 916310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Zephy and J. Ahmad, “Type 2 diabetes mellitus: role of melatonin and oxidative stress,” Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 9, no. 2, pp. 127–131, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Pitocco, M. Tesauro, R. Alessandro, G. Ghirlanda, and C. Cardillo, “Oxidative stress in diabetes: implications for vascular and other complications,” International Journal of Molecular Sciences, vol. 14, no. 11, pp. 21525–21550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Alkhoury, S. M. Parkin, S. Homer-Vanniasinkam, and A. M. Graham, “Chronic homocysteine exposure upregulates endothelial adhesion molecules and mediates leukocyte: endothelial cell interactions under flow conditions,” European Journal of Vascular and Endovascular Surgery, vol. 41, no. 3, pp. 429–435, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ramesh, C. N. Morrell, C. Tarango et al., “Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2,” Journal of Clinical Investigation, vol. 121, no. 1, pp. 120–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. D. Crowley, “The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension,” Antioxidants & Redox Signaling, vol. 20, no. 1, pp. 102–120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Panagiotakos, C. Pitsavos, I. Skoumas et al., “The association between prehypertension status and inflammatory markers related to atherosclerotic disease; The ATTICA study,” Atherosclerosis Supplements, vol. 6, no. 1, p. 164, 2005. View at Google Scholar
  23. K. Majumder and J. P. Wu, “Molecular targets of antihypertensive peptides: understanding the mechanisms of action based on the pathophysiology of hypertension,” International Journal of Molecular Sciences, vol. 16, no. 1, pp. 256–283, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Kohlgruber and L. Lynch, “Adipose tissue inflammation in the pathogenesis of Type 2 diabetes,” Current Diabetes Reports, vol. 15, no. 11, article 92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. M. H. Y. Chng, M. N. Alonso, S. E. Barnes, K. D. Nguyen, and E. G. Engleman, “Adaptive immunity and antigen-specific activation in obesity-associated insulin resistance,” Mediators of Inflammation, vol. 2015, Article ID 593075, 15 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Jeltsch and P. Chambon, “The complete nucleotide sequence of the chicken ovotransferrin mRNA,” European Journal of Biochemistry, vol. 122, no. 2, pp. 291–295, 1982. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Y. Ko, A. F. Mendonca, and D. U. Ahn, “Effect of ethylenediaminetetraacetate and lysozyme on the antimicrobial activity of ovotransferrin against Listeria monocytogenes,” Poultry Science, vol. 87, no. 8, pp. 1649–1658, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Sellier, M. L. Vidal, F. Baron et al., “Estimations of repeatability and heritability of egg albumen antimicrobial activity and of lysozyme and ovotransferrin concentrations,” British Poultry Science, vol. 48, no. 5, pp. 559–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Aguilera, L. M. Quiros, and J. F. Fierro, “Transferrins selectively cause ion efflux through bacterial and artificial membranes (FEBS 27456) (vol 548, pg 5, 2003),” FEBS Letters, vol. 560, no. 1–3, p. 226, 2004. View at Google Scholar
  30. F. Giansanti, L. Leboffe, F. Angelucci, and G. Antonini, “The nutraceutical properties of ovotransferrin and its potential utilization as a functional food,” Nutrients, vol. 7, no. 11, pp. 9105–9115, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Majumder, G. Liang, Y. Chen, L. Guan, S. T. Davidge, and J. Wu, “Egg ovotransferrin-derived ACE inhibitory peptide IRW increases ACE2 but decreases proinflammatory genes expression in mesenteric artery of spontaneously hypertensive rats,” Molecular Nutrition and Food Research, vol. 59, no. 9, pp. 1735–1744, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Giansanti, M. T. Massucci, M. F. Giardi et al., “Antiviral activity of ovotransferrin derived peptides,” Biochemical and Biophysical Research Communications, vol. 331, no. 1, pp. 69–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Giansanti, P. Rossi, M. T. Massucci et al., “Antiviral activity of ovotransferrin discloses an evolutionary strategy for the defensive activities of lactoferrin,” Biochemistry and Cell Biology, vol. 80, no. 1, pp. 125–130, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Siciliano, B. Rega, M. Marchetti, L. Seganti, G. Antonini, and P. Valenti, “Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection,” Biochemical and Biophysical Research Communications, vol. 264, no. 1, pp. 19–23, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Kim, S. H. Moon, D. U. Ahn, H. D. Paik, and E. Park, “Antioxidant effects of ovotransferrin and its hydrolysates,” Poultry Science, vol. 91, no. 11, pp. 2747–2754, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Huang, S. Shen, C. Nimalaratne, S. Li, K. Majumder, and J. Wu, “Effects of addition of egg ovotransferrin-derived peptides on the oxygen radical absorbance capacity of different teas,” Food Chemistry, vol. 135, no. 3, pp. 1600–1607, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. S. H. Moon, J. H. Lee, Y. J. Lee et al., “Screening for cytotoxic activity of ovotransferrin and its enzyme hydrolysates,” Poultry Science, vol. 92, no. 2, pp. 424–434, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. S. H. Moon, J. H. Lee, D. U. Ahn, and H.-D. Paik, “In vitro antioxidant and mineral-chelating properties of natural and autocleaved ovotransferrin,” Journal of the Science of Food and Agriculture, vol. 95, no. 10, pp. 2065–2070, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. N. C. Rath, N. B. Anthony, L. Kannan et al., “Serum ovotransferrin as a biomarker of inflammatory diseases in chickens,” Poultry Science, vol. 88, no. 10, pp. 2069–2074, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Xie, G. R. Huff, W. E. Huff, J. M. Balog, and N. C. Rath, “Effects of ovotransferrin on chicken macrophages and heterophil-granulocytes,” Developmental and Comparative Immunology, vol. 26, no. 9, pp. 805–815, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Xie, G. R. Huff, W. E. Huff, J. M. Balog, P. Holt, and N. C. Rath, “Identification of ovotransferrin as an acute phase protein in chickens,” Poultry Science, vol. 81, no. 1, pp. 112–120, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. W.-Y. Huang, S. T. Davidge, and J. P. Wu, “Bioactive natural constituents from food sources—potential use in hypertension prevention and treatment,” Critical Reviews in Food Science and Nutrition, vol. 53, no. 6, pp. 615–630, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Majumder, S. Chakrabarti, S. T. Davidge, and J. Wu, “Structure and activity study of egg protein ovotransferrin derived peptides (IRW and IQW) on endothelial inflammatory response and oxidative stress,” Journal of Agricultural and Food Chemistry, vol. 61, no. 9, pp. 2120–2129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Huang, S. Chakrabarti, K. Majumder, Y. Jiang, S. T. Davidge, and J. Wu, “Egg-derived peptide IRW inhibits TNF-α-induced inflammatory response and oxidative stress in endothelial cells,” Journal of Agricultural and Food Chemistry, vol. 58, no. 20, pp. 10840–10846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Majumder, S. Chakrabarti, J. S. Morton et al., “Egg-derived tri-peptide IRW exerts antihypertensive effects in spontaneously hypertensive rats,” PLoS ONE, vol. 8, no. 11, Article ID e82829, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Majumder, S. Chakrabarti, J. S. Morton et al., “Egg-derived ACE-inhibitory peptides IQW and LKP reduce blood pressure in spontaneously hypertensive rats,” Journal of Functional Foods, vol. 13, pp. 50–60, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. N.-Y. Lee, J.-T. Cheng, T. Enomoto, and Y. Nakano, “One peptide derived from hen ovotransferrin as pro-drug to inhibit angiotensin converting enzyme,” Journal of Food and Drug Analysis, vol. 14, no. 1, pp. 31–35, 2006. View at Google Scholar · View at Scopus
  48. J. Wu and A. Acero-Lopez, “Ovotransferrin: structure, bioactivities, and preparation,” Food Research International, vol. 46, no. 2, pp. 480–487, 2012. View at Publisher · View at Google Scholar · View at Scopus